Diabetes is a growing global epidemic. Atrogi has discovered an unprecedented insulin independent approach to treat Type 2 Diabetes.

Atrogi was founded in 2013 by professor Tore Bengtsson with support from private investors. Professor Bengtsson has been conducting ground-breaking research on adrenergic signaling at Stockholm University for over 15 years and discovered how to selectively stimulate blood glucose uptake in skeletal muscle. This evidence is used to develop a treatment of T2D that produces minimal side effects.